×
About 17,713 results

ALLMedicine™ Atopic Dermatitis Center

Research & Reviews  5,329 results

Atopic dermatitis in adolescents with acne vulgaris.
https://doi.org/10.23822/EurAnnACI.1764-1489.244
European Annals of Allergy and Clinical Immunology; Todo Bom Costa S, Tapadinhas C et. al.

Jan 27th, 2022 - Atopic dermatitis in adolescents with acne vulgaris.|2022|Todo Bom Costa S,Tapadinhas C,Sampaio ML,|

Primary atopic disorders and chronic skin disease.
https://doi.org/10.1111/pai.13633
Pediatric Allergy and Immunology : Official Publication O... Cinicola BL, Corrente S et. al.

Jan 27th, 2022 - Primary atopic disorders (PADs) are monogenic diseases characterized by allergy or atopy-related symptoms as fundamental features. In patients with PADs, primary immune deficiency and immune dysregulation symptoms are usually coexist. Chronic skin...

Assessment of Changes in Diversity in Dermatology Clinical Trials Between 2010-2015 and...
https://doi.org/10.1001/jamadermatol.2021.5596
JAMA Dermatology; Chen V, Akhtar S et. al.

Jan 27th, 2022 - Although there have been increased efforts in dermatologic research to improve representation of patient sex, race, and ethnicity, there are limited data evaluating resulting changes. To characterize the diversity of participants in dermatologic c...

New opportunities with biologic treatments in pediatric allergic and respiratory diseases.
https://doi.org/10.1111/pai.13617
Pediatric Allergy and Immunology : Official Publication O... Tenero L, Piacentini G

Jan 27th, 2022 - In the last 20 years, the introduction of monoclonal antibodies has dramatically changed allergic diseases. At present, several monoclonal antibodies are approved for treating asthma, atopic dermatitis, chronic spontaneous urticaria, and chronic s...

Rapid response to dupilumab treatment in children with moderate-to-severe atopic dermat...
https://doi.org/10.1111/pai.13623
Pediatric Allergy and Immunology : Official Publication O... Votto M, Delle Cave F et. al.

Jan 27th, 2022 - Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease characterized by itch and clinical heterogeneity regarding the age of onset, morphology, distribution, and severity of lesions. Severe AD has a significant impact on the qua...

see more →

Guidelines  9 results

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis...
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Considerations on biologicals for patients with allergic disease in times of the COVID-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300800
Allergy Vultaggio A, Agache I et. al.

Jun 6th, 2020 - The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex pat...

European task force on atopic dermatitis position paper: treatment of parental atopic d...
https://doi.org/10.1111/jdv.15709
Journal of the European Academy of Dermatology and Venere... Vestergaard C, Wollenberg A et. al.

Jun 25th, 2019 - Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the trea...

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) ...
https://doi.org/10.1111/jdv.14891
Journal of the European Academy of Dermatology and Venere... Wollenberg A, Barbarot S et. al.

Apr 21st, 2018 - This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic revi...

The microbiome in allergic disease: Current understanding and future opportunities-2017...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899886
The Journal of Allergy and Clinical Immunology; Huang YJ, Marsland BJ et. al.

Mar 5th, 2017 - PRACTALL is a joint initiative of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and ...

see more →

Drugs  449 results see all →

Clinicaltrials.gov  344 results

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT03559270

Jan 19th, 2022 - This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD).

A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
https://clinicaltrials.gov/ct2/show/NCT05029895

Jan 19th, 2022 - Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, these studies included a limited number of adolescent p...

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT03915496

Jan 13th, 2022 - B7451037 is a randomized, double-blind, placebo-controlled, parallel-group, Phase 2a study to investigate the mechanism of action of PF-04965842 by correlating efficacy outcomes with changes from baseline in key skin and blood biomarkers in adult ...

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT04773587

Jan 13th, 2022 - This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream or vehicle is applied once daily for 4 weeks to subjects with atopic dermatitis.

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
https://clinicaltrials.gov/ct2/show/NCT04773600

Jan 13th, 2022 - This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream or vehicle is applied once daily for 4 weeks to subjects with atopic dermatitis.

see more →

News  929 results

Pruritus in elderly patients: Not a diagnosis
https://www.mdedge.com/dermatology/article/251202/atopic-dermatitis/pruritus-elderly-patients-not-diagnosis
Doug Brunk

Jan 26th, 2022 - Once they reach retirement age, increasing numbers of patients come to Eric L. Simpson, MD, complaining of an itchy rash that has appeared seemingly out of the blue.

Key clinical point: Children aged <5 years with atopic dermatitis (AD) show a disease severity-dependent increased risk for poor sleep health and attention dysregulation (AdR). Major finding: AD-in...
https://www.mdedge.com/dermatology/article/251093/atopic-dermatitis/key-clinical-point-children-aged

Jan 25th, 2022 - Key clinical point: Antibiotic use in infants younger than 12 months is associated with an increased risk of developing atopic dermatitis (AD) if shared familial and environmental factors are disregarded. Major finding: A higher proportion of infa.

Patients with atopic dermatitis at higher risk for COVID-19 infection
https://www.mdedge.com/dermatology/article/251090/atopic-dermatitis/patients-atopic-dermatitis-higher-risk-covid-19

Jan 25th, 2022 - Key clinical point: Patients with atopic dermatitis (AD) showed a significantly higher risk of contracting COVID-19 infection irrespective of comorbidities and other demographic factors. Major finding: Patients with vs.

Upadacitinib and topical corticosteroids combo safe in mild-to-moderate atopic dermatitis
https://www.mdedge.com/dermatology/article/251088/atopic-dermatitis/upadacitinib-and-topical-corticosteroids-combo-safe

Jan 25th, 2022 - Key clinical point: The combination of upadacitinib and topical corticosteroids (TCS) showed a favorable safety profile in moderate-to-severe atopic dermatitis (AD). Major finding: Treatment-emergent adverse events (TEAE) were reported by 56% and.

Atopic Dermatitis: A supplement to Dermatology News
https://www.mdedge.com/dermatology/article/250775/atopic-dermatitis/atopic-dermatitis-supplement-dermatology-news

Jan 14th, 2022 - PATIENT SATISFACTION WITH TREATMENT REDUCING ITCH BURDEN OF DISEASE IN BLACK PATIENTS BATHING RECOMMENDATIONS Read More.

see more →

Patient Education  25 results see all →